WHAT IS CINGAL?
CINGAL® is the first and only approved combination viscosupplement formulated to provide the benefit of a cross-linked hyaluronic acid and a fast acting steroid.
CINGAL® is a novel combination HA plus steroid single-injection treatment for the pain associated with osteoarthritis. CINGAL® combines the high molecular weight cross-linked hyaluronic acid (HA) formulation of MONOVISC® with a corticosteroid for additional short-term pain relief.
CINGAL® is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints. CINGAL® is well suited for rapid and long term relief of the symptoms of human joint dysfunctions such as osteoarthritis.
The unique function of CINGAL
CINGAL combines Anika’s proprietary cross-linked hyaluronic acid formulation, MONOVISC with proven effects through 6 months, with a well-established FDA approved steroid, triamcinolone hexacetonide.
Only CINGAL works by combining the best of fast acting steroids with a long-lasting viscosupplement to deliver rapid pain relief proven to last through 6 months.
Fast Acting. Long Lasting.
The unique combination of high concentration cross-linked hyaluronic acid formulation with a well-established FDA approved steroid provides rapid pain relief that lasts through 6 months.
CINGAL shows highly statistically significant improvement compared to saline at all secondary endpoint at 26 weeks
1. Anika data on file
2. CINGAL 13-01, a randomized, double-blind, placebo-controlled, active comparator Phase 3 study